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Abstract 
            Brugada syndrome is an arrhythmogenic disease characterized by an ECG pattern of 
coved-type ST segment elevation in the right precordial leads and an increased risk of sudden 
cardiac death (SCD) as a result of polymorphic ventricular tachyarrhythmia or ventricular 
fibrillation. Data from large patient studies and a meta-analysis of previous reports have shown 
that patients with a history of syncope or SCD and a spontaneous type 1 Brugada ECG are at 
high risk for SCD. However, risk stratification of asymptomatic patients with Brugada type ECG 
is still a challenge. In particular, the use of electrophysiological study (EPS) for risk stratification 
remains controversial. Although some investigators have reported the possibility of use of EPS 
for distinguishing between high- and low-risk patients with Brugada type ECG, no precise 
predictor of risk for SCD in asymptomatic patients has yet been determined. The approach to 
treatment of these patients is thus still unclear. Large clinical prospective studies with uniform 
diagnostic criteria and protocols for EPS as well as extended follow-up periods of over ten years 
are required for prediction of SCD.
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            Since its description in 19921, Brugada syndrome has been the focus of many clinical and 
research investigations as one of the leading causes of sudden cardiac death (SCD) in young 
adults. Recent large prospective studies have indicated that symptomatic patients with at least 
one   episode   of   syncope   or   documented   VF   are   at   high   risk   of   malignant   ventricular 
tachyarrhythmias because of the high rate of recurrence of VF2-4. On the basis of this evidence, 
recommendations for treatment of this syndrome were described in the recently published 
consensus report5. The report recommends that symptomatic patients displaying type 1 (coved-
type ST segment elevation ≥ 0.2 mV followed by a negative T wave) Brugada type ECG (either 
spontaneously or after sodium channel blockade) who present with aborted SCD and related 
symptoms such as syncope, seizure, or nocturnal agonal respiration should undergo placement of 
an implantable cardioverter defibrillator (ICD) after non-cardiac causes have been ruled out. 
However, risk stratification of asymptomatic patients with Brugada type ECG is still a challenge.
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Risk stratification of asymptomatic patients with Brugada type ECG                       
            Some reports have noted the natural history of asymptomatic patients with Brugada type 
ECG. Data from the largest patient series have shown that 8% of patients without previous 
cardiac arrest had SCD or documented ventricular fibrillation during a mean follow-up of 24 
months4. In that study, patients with syncope and family members of patients with Brugada 
syndrome were included. The risk of these events was highest in patients who were men, had 
suffered syncope, had a spontaneously abnormal type 1 Brugada ECG, and had inducible 
ventricular tachyarrhythmias during electrophysiological study (EPS). Priori et al. found that 
14% of patients with spontaneously abnormal Brugada type ECG (ST segment elevation ≥ 0.2 
mV; whether type 1 ECG was observed was not specified) without previous syncope suffered 
cardiac arrest during a mean follow-up of 34 months, and that patients with spontaneously 
abnormal Brugada type ECG had relatively high risk of SCD2. In their study, family members of 
patients (35%) with Brugada syndrome were included. However, other studies reported a much 
lower risk of these events in asymptomatic patients6-9. Eckardt et al. found that only 0.8% of 
patients without previous cardiac arrest or syncope had SCD and documented ventricular 
fibrillation during a mean follow-up of 40 months6. They also reported that one of the significant 
predictors for risk of SCD was a spontaneously abnormal type 1 Brugada ECG. In the three 
Japanese studies, as well, although numbers of patients were relatively small and diagnostic 
criteria differed (not all patients had type 1 ECG), only 0.4 - 0.5% of sporadic patients without 
previous cardiac arrest or syncope had SCD per year7-9.                                             
            These findings suggest that, although the risk of SCD in sporadic asymptomatic patients 
may be much lower, a spontaneously abnormal type 1 Brugada ECG might be a predictor for 
SCD   in   these   patients.                                                          
            Recent studies have suggested that combined noninvasive ECG markers may be helpful 
in risk stratification. Atarashi et al. reported the feasibility of risk stratification using the width of 
the S wave and ST segment elevation magnitude in the right precordial leads on surface ECG10. 
Some reports noted that signal-averaged ECG (SAECG) has been useful for identifying patients 
at high risk11,12. Other studies have suggested that circadian and daily fluctuations in ECG and 
SAECG could be useful for distinguishing between high- and low-risk patients13-15. The value of 
these markers in combination remains to be tested in a large prospective study.                 
Role of electrophysiological study in risk stratification                                             
            The predictive value of inducibility of sustained ventricular arrhythmias during EPS is 
still controversial. Although Brugada et al. have supported the value of EPS based on the results 
for the largest series of patients4, two other large studies have not confirmed their findings2,6. 
Recently, Gehi et al. performed a meta-analysis of prognostic studies of patients with Brugada 
syndrome16. The results of their meta-analysis did not support the value of EPS as a predictor of 
cardiac events. The heterogeneity found in the value of EPS for risk stratification may be due to 
methodological differences in stimulation protocols and/or criteria for positive EPS2,6. A 
standard methodology is needed to determine the value of EPS for risk stratification in patients 
with   Brugada   syndrome17.                                                                          
Therapeutic approach to asymptomatic patients with Brugada type ECG                       
            Currently, implantation of an ICD is the only effective treatment for this syndrome. 
However, various other treatments have been attempted to prevent SCD. Quinidine has been 
shown to be effective for prevention of SCD18-20. Tedisamil and isoproterenol have been reported 
to normalize the ST segment elevation in patients with this syndrome21,22. The phosphodiesterase 
III inhibitor, cilostazol, has also recently been reported to be useful23. However, the long-term 
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efficacy   of   these   treatments   in   preventing   SCD   is   still   unclear.                              
               For symptomatic patients with type 1 Brugada ECG (either spontaneously or after 
sodium channel blockade), ICD implantation is recommended in the report of the second 
consensus conference5. With regard to treatment of asymptomatic patients, the indications for 
use of ICD remain controversial. The report of the second consensus conference recommends 
ICD implantation for asymptomatic patients with a family history of SCD, type 1 Brugada ECG 
(either   spontaneously   or   after   sodium   channel   blockade),   and   inducible   ventricular 
tachyarrhythmias during EPS. However, the meta-analysis of prognostic studies of patients with 
Brugada syndrome by Gehi et al. did not support the value of EPS and family history of SCD as 
predictors of cardiac events. For asymptomatic patients with spontaneous type 1 Brugada ECG 
without family history of SCD, the indications for treatment remain unclear, since the value of 
EPS is still controversial, as noted above. Asymptomatic patients with type 1 Brugada ECG after 
sodium channel blockade and without family history of SCD appear to be at low risk for SCD2.  
Treatment is currently not recommended for these patients.                                           
            There has been some lack of uniformity in the diagnostic criteria and protocols for EPS, 
and follow-up periods have been limited. Large clinical prospective studies with uniform 
diagnostic criteria and protocols for EPS as well as extended follow-up periods of over ten years 
are required for prediction risk of SCD in asymptomatic patients with Brugada syndrome. 
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